Adam Resnick

Has grant

Director

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Deciphering the 3D genome of pediatric brain tumors

Open Date: 2022-09-20

Close Date: 2024-09-19

Grant: Close

Deep Phenotyping Children with Congenital Anomalies and Cancer Enrolled in Project:EveryChild

Open Date: 2022-05-01

Close Date: 2025-04-30

Grant: Close

Data Management and Portal for the INCLUDE (DAPI) Project

Open Date: 2020-09-26

Close Date: 2025-08-31

Grant: Close

Kids First Data Resource Center (KFDRC): Harnessing Data-Driven Opportunities in the Present on behalf of the Future of Common Fund Data Ecosystem (CFDE)

Open Date: 2020-09-25

Close Date: 2024-09-24

Grant: Close

Functional characterization and drug targeting of MET gene fusions in DMGs

Open Date: 2020-07-01

Close Date: 2022-02-28

Articles (18)

Background/Objectives: Prostate-specific membrane antigen (PSMA) is a well-established target in prostate cancer therapy that has shown potential as a theranostic target across non-central nervous system (CNS) and CNS tumor types. We aimed to investigate the pan-tissue expression pattern of the PSMA-encoding gene FOLH1 to assess whether transcriptome profiling can inform tumor diagnostic and theranostic probes. Methods: We assessed FOLH1 expression from the Open Pediatric Cancer Project (OpenPedCan, n = 2132 specimens), the Cancer Genome Atlas (TCGA, n = 10,411 specimens), and the Genotype Tissue Expression Project (GTEx, n = 17,382 specimens) in relation to published reports of PSMA radionuclide uptake in various tumors. Results: When comparing FOLH1 expression across tumor versus normal tissues, we found that non-CNS tumors exhibiting elevated expression of at least two-fold (FDR < 0.05) were reported to have significant PSMA radionuclide uptake in contrast to tumors with less than a two-fold elevation or with lower expression of FOLH1 relative to normal tissues. Notably, CNS tumors universally exhibited lower expression of FOLH1 relative to normal brain tissue, but we observed considerable variation in the expression of blood–tumor barrier (BTB) components associated with reports of BTB integrity and uptake of PSMA radiotracers. Conclusions: Large-scale transcriptomics data may help guide the application of PSMA-based radionuclide therapies in non-CNS tumors, but care should be taken to account for BTB effects in CNS tumors when assessing the potential for radionuclide success. This study demonstrates that FOLH1 showed a lack of tumor-specific expression for both adult and pediatric CNS tumors when compared to normal brain tissue, suggesting that PSMA is not a desirable target in brain tumors.

Year:

2025

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends.Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG.Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201.Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial.Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability.Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders.Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls.Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials).Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201.Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201.Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201.Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells.Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase.Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells.Fig. S14. ONC201 increases global H3K27me3 in patient samples.Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2025

The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterized the prevalence and clinical significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identified germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lacked clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% had putative somatic second hits or loss of function tumor alterations. Finally, we linked pathogenic germline variation with novel somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.

Year:

2025

Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults ( P P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.

Year:

2025

Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.

Year:

2025

Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma

Year:

2025

Background Central nervous system (CNS) tumors lead to cancer-related mortality in children. Genetic ancestry-associated cancer prevalence and outcomes have been studied but are limited. Methods We performed genetic ancestry prediction in 1,452 pediatric patients with paired normal and tumor whole genome sequencing from the Open Pediatric Cancer (OpenPedCan) project to evaluate the influence of reported race and ethnicity and ancestry-based genetic superpopulations on tumor histology, molecular subtype, survival, and treatment. Results Predicted superpopulations included African (AFR, N = 153), Admixed American (AMR, N = 222), East Asian (EAS, N = 67), European (EUR, N = 968), and South Asian (SAS, N = 42). Reported race and ethnicity and ancestry-based genetic superpopulations were non-randomly associated (P < .001). Patients with an atypical teratoid rhabdoid tumor or meningioma were enriched for AFR ancestry (OR = 2.6, FDR = 0.01; OR = 2.9, FDR = 0.01, respectively). Among KIAA1549::BRAF fusion-positive low-grade glioma (LGG) diagnoses, EAS and SAS patients disproportionately harbored exon 15:09 breakpoints (FDR < 0.05), and AMR patients demonstrated rare breakpoints, which were associated with lesser degree of surgical resection and worse event-free survival (EFS) versus other breakpoints (hazard ratio (HR) = 4.6, P = .03). Non-EUR and AMR patients with germ cell tumors and SHH-activated medulloblastoma, respectively, exhibited worse EFS relative to EUR patients (HR = 12.1, P < .01; HR = 5.2, P = .03) and AFR patients with LGG (HR = 16.4, P < .01) or ependymoma (HR = 5.5, P = .02) had worse overall survival compared to EUR patients. We observed a higher frequency of clinical trial enrollment among AMR patients across tumor histologies (OR = 2.0, P ≤ .01), but increased utilization of photon versus proton radiation relative to other superpopulations (OR = 0.55, P= .04). Conclusions Genetic ancestry-associated differences exist across pediatric CNS tumor histological and molecular subtypes from PBTA and PNOC. Further investigation into genetic and socioeconomic factors contributing to these observed inequities is needed.

Year:

2025

To overcome the paucity of known tumor-specific surface antigens in pediatric high-grade glioma (pHGG), we contrasted splicing patterns in pHGGs and normal brain samples. Among alternative splicing events affecting extracellular protein domains, the most pervasive alteration was the skipping of ≤30 nucleotide-long exons. Several of these skipped microexons mapped to L1-IgCAM family members, such as NRCAM . Bulk and single-nuclei short- and long-read RNA-seq revealed uniform skipping of NRCAM microexons 5 and 19 in virtually every pHGG sample. Importantly, the Δex5Δex19 (but not the full-length) NRCAM proteoform was essential for pHGG cell migration and invasion in vitro and tumor growth in vivo. We developed a monoclonal antibody selective for Δex5Δex19 NRCAM and demonstrated that “painting” of pHGG cells with this antibody enables killing by T cells armed with an FcRI-based universal immune receptor. Thus, pHGG-specific NRCAM and possibly other L1-IgCAM proteoforms are promising and highly selective targets for adoptive immunotherapies.

Year:

2025

Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (84)

Matthew Hall

Associate Clinical Professor

Florida International University

UNITED STATES
View details

Chandan Kumar

Associate Research Scientist

University of Michigan

UNITED STATES
View details

Ali Nabavizadeh

University of Pennsylvania

UNITED STATES
View details

Raja Mazumder

George Washington University

UNITED STATES
View details

Sharon Diskin

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Mariella Spalato Ceruso

Institut Bergonié

FRANCE
View details

Sebastian Waszak

Tenure Track Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Jordan R Hansford

Oncologist

University of Melbourne

AUSTRALIA
View details

Mariella Filbin

Dana-Farber Cancer Institute

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Sarah Tasian

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Yoshie Umemura

Barrow Neurological Institute

UNITED STATES
View details

Miriam Bornhorst

Ann and Robert H Lurie Children's Hospital of Chicago

UNITED STATES
View details

Rajen J. Mody

University of Michigan

UNITED STATES
View details

Angela Waanders

Associate Professor

Ann and Robert H Lurie Children's Hospital of Chicago

UNITED STATES
View details

Uri Tabori

Section Head of Neuro-Oncology

Hospital for Sick Children

CANADA
View details

Frank Lin

Baylor College of Medicine Department of Pediatrics

UNITED STATES
View details

Holly Lindsay

Associate Professor

University of Colorado Health

UNITED STATES
View details

Ingrid Øra

MD, PhD, Assoc Prof

Lund University

SWEDEN
View details

minesh mehta

Chair

Florida International University

UNITED STATES
View details

Birgit Geoerger

Université Paris-Saclay

FRANCE
View details

Anna Schwendeman

-

UNITED STATES
View details

Daniel J. Powell

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Timothy Cloughesy

Director of NeuroOncology Program/Professor

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Jonathon Keeney

Assistant Research Professor

George Washington University

UNITED STATES
View details

David Ziegler

Professor

University of New South Wales

AUSTRALIA
View details

Michelle M Kim

University of Michigan

UNITED STATES
View details

Eugene Hwang

Chief

Children's National Medical Center

UNITED STATES
View details

Hagen U Tilgner

Associate Professor

Weill Cornell Medicine

UNITED STATES
View details

Sriram Venneti

Professor

University of Michigan

UNITED STATES
View details

Alexander Drilon

Thomas Jefferson University Hospital

UNITED STATES
View details

Chantel Cacciotti

Western University

CANADA
View details

Chris Jones

Professor of Childhood Brain Tumour Biology

Institute of Cancer Research

UNITED KINGDOM
View details

Maura Massimino

Direttore S.C

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Kara Maxwell

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Kathryn McFadden

Associate Clinical Professor

Izaak Walton Killam Health Centre

CANADA
View details

Aleksandar Mihajlovic

Head of Operations

APIS Assay Technologies Ltd

UNITED KINGDOM
View details

elisabetta schiavello

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Lili Zhao

Professor

Northwestern University

UNITED STATES
View details

Charles Burant

University of Michigan

UNITED STATES
View details

Daniel Orbach

-

FRANCE
View details

Sabine Mueller

Adjunt Associate Professor

University of California

UNITED STATES
View details

Nathalie Agar

Principal Investigator

Brigham and Women's Hospital

UNITED STATES
View details

Yoseph Barash

Proffesor

University of Pennsylvania

UNITED STATES
View details

Christopher L Moertel

University of Minnesota

UNITED STATES
View details

Nathan Robison

Assistant Professor of Clinical Pediatrics

University of Southern California Keck School of Medicine

UNITED STATES
View details

Jo Lynne Rokita

Director, Brain Tumor Institute Bioinformatics Core

Children's National Health System

UNITED STATES
View details

Deanne Taylor

Research Associate Professor

University of Pennsylvania

UNITED STATES
View details

Nicholas Gottardo

University of Western Australia

AUSTRALIA
View details

Rajan Jain

Professor

NYU Langone Health

UNITED STATES
View details

Rawan Hammad

Assistant professor

king abdulaziz university

SAUDI ARABIA
View details

John Maris

PI

University of Pennsylvania

UNITED STATES
View details

Matthew Dun

Professor Paediatric Heamatology/Oncology Research

Hunter Medical Research Institute

AUSTRALIA
View details

Nada Jabado

Professor

McGill University

CANADA
View details

Jamie Spangler

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Susanne Schmidt

Group Leader

University of Bonn

GERMANY
View details

Mathieu Quesnel-Vallières

Assistant Professor

Université de Sherbrooke

CANADA
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Marilyn Li

Associate Chair and Vice Chief of Division of Genomic Diagnoatics

Children's Hospital of Philadelphia

UNITED STATES
View details

Andrea T. Franson

-

UNITED STATES
View details

Lenka Krsková

First Faculty of Medicine Charles University and University Hospital Motol

CZECH REPUBLIC
View details

Javad Nazarian

Lead, DMG Research Center

-

SWITZERLAND
View details

Shankar Subramaniam

University of California, San Diego

UNITED STATES
View details

Chan Chung

Principal investigator

Daegu Gyeongbuk Institute of Science and Technology

SOUTH KOREA
View details

Theodore Laetsch

Associate Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Michal Zapotocky

University Hospital in Motol

CZECH REPUBLIC
View details

Benjamin M Ellingson

Professor

University of California, Los Angeles

UNITED STATES
View details

Michael Prados

University of California

UNITED STATES
View details

Andrei Thomas-Tikhonenko

Division Chief

Children's Hospital of Philadelphia

UNITED STATES
View details

Audrey-Anne Lamoureux

Université de Montréal

CANADA
View details

Thomas De Raedt

Assistant Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Donald Parsons

Professor

Baylor College of Medicine

UNITED STATES
View details

Alexander Lachmann

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Alexander G. Weil

-

CANADA
View details

Alex Brown

Professor

Telethon Kids Institute

AUSTRALIA
View details

Thinh Quoc Nguyen

Thomas Jefferson University

UNITED STATES
View details

Aleksandar Milosavljevic

Baylor College of Medicine

UNITED STATES
View details

Kai Wang

Professor

University of Pennsylvania

UNITED STATES
View details

Avi Ma'ayan

Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Daniel R. Wahl

University of Michigan

UNITED STATES
View details

Nicolas U. Gerber

University Children's Hospital Zurich

SWITZERLAND
View details

Jacques Grill

Head day care

Gustave Roussy

FRANCE
View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES
View details

Sharon L Gardner

Associate Professor (Clinical) of Pediatrics

NYU School of Medicine

UNITED STATES
View details